BiomeCRC^®– Early detection microbiome test for colorectal cancer

Available 2023

BiomeCRC is a colorectal cancer preventive screening test based on the intestinal microbiome. The tool is powered by the proven BiomeDx platform and data from numerous clinical trials. Ongoing research in collaboration with the Medical University of Vienna includes over 1000 probands.

Product features

Cost efficient & non invasive
Able to differentiate tumour stages
Easily scaleable via screening programs

BiomeFMT – Stool donor identification for non-responders to cancer immunotherapy

Available 2023

BiomeFMT is a novel stool sample test – in development. BiomeFMT will be used to identify ideal donors for fecal microbiota transplantation for non-responders to cancer immunotherapy (ICI). For the first time it will be possible to screen large amounts of samples from biobanks in order to find potential super-responders to ICI.

Product features

Identifies donors for fecal microbiota transplantation
Unlock the full power of cancer immunotherapy
Scalable for broad clinical use

myBioma^®– Because your health starts in the gut

Available on mybioma.com

Our well-established lifestyle product myBioma^® is available for any European citizen to analyse one’s gut health. The microbiome report is available via PDF and mobile app on iOS and Android. The results include information on diversity, nutrition, health and dietary recommendations as well as a large network of therapists.

More information about myBioma^® can be found at www.mybioma.com.

Partner solution – End-to-end solution for microbiome analysis

Clinical trials, pilot projects, discovery

As a research-driven company, we collaborate with academic institutions and partners to uncover new correlations in the microbiome. For this purpose, we have developed an own study pipeline that performs statistical and machine learning algorithms in regards to the main hypothesis of the project.